BR112016006926A8 - uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido - Google Patents

uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido Download PDF

Info

Publication number
BR112016006926A8
BR112016006926A8 BR112016006926A BR112016006926A BR112016006926A8 BR 112016006926 A8 BR112016006926 A8 BR 112016006926A8 BR 112016006926 A BR112016006926 A BR 112016006926A BR 112016006926 A BR112016006926 A BR 112016006926A BR 112016006926 A8 BR112016006926 A8 BR 112016006926A8
Authority
BR
Brazil
Prior art keywords
prevention
improvement
composition
cell
acid
Prior art date
Application number
BR112016006926A
Other languages
English (en)
Other versions
BR112016006926B1 (pt
BR112016006926A2 (pt
Inventor
William George Forbes Iain
Forbes William
Original Assignee
Calscience Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calscience Int Ltd filed Critical Calscience Int Ltd
Publication of BR112016006926A2 publication Critical patent/BR112016006926A2/pt
Publication of BR112016006926A8 publication Critical patent/BR112016006926A8/pt
Publication of BR112016006926B1 publication Critical patent/BR112016006926B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

a presente invenção refere-se ao uso da composição para a prevenção, melhora e/ ou tratamento de distúrbios e de doenças envolvendo a senescência da célula, tecido ou órgão, ou para a prevenção, melhora e/ ou tratamento dos distúrbios e doenças envolvendo a tensão do órgão, tecido, célula causada por meio de um processo inflamatório, a composição compreendendo um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico, ou um derivado, isômero ou seu sal.
BR112016006926-9A 2013-09-30 2014-09-19 Uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido BR112016006926B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1317286.1A GB201317286D0 (en) 2013-09-30 2013-09-30 Composition and Use
GB1317286.1 2013-09-30
PCT/GB2014/052863 WO2015044649A1 (en) 2013-09-30 2014-09-19 Compositions comprising a conjugate of quinic acid with caffeic acid, cosmetic and therapeutic uses

Publications (3)

Publication Number Publication Date
BR112016006926A2 BR112016006926A2 (pt) 2017-08-01
BR112016006926A8 true BR112016006926A8 (pt) 2020-02-27
BR112016006926B1 BR112016006926B1 (pt) 2020-09-24

Family

ID=49585061

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006926-9A BR112016006926B1 (pt) 2013-09-30 2014-09-19 Uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido

Country Status (5)

Country Link
US (1) US20160228394A1 (pt)
EP (1) EP3052074A1 (pt)
BR (1) BR112016006926B1 (pt)
GB (1) GB201317286D0 (pt)
WO (1) WO2015044649A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
GB201502268D0 (en) * 2015-02-11 2015-04-01 Calscience Internat Ltd Dental composition and use
FR3057772B1 (fr) * 2016-10-26 2020-10-02 Plant Advanced Tech Pat Derives d'acides quiniques polysubstitues et leurs utilisations
KR101756740B1 (ko) * 2016-12-30 2017-07-11 주식회사 파미니티 치주조직 재생 촉진용 조성물
WO2018124508A1 (ko) * 2016-12-30 2018-07-05 연세대학교 산학협력단 3,5-디카페오일퀴닉에시드 또는 국화 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
KR101852570B1 (ko) 2017-03-14 2018-04-27 대한민국(농림축산식품부 농림축산검역본부장) 1,5-디카페오일퀴닉산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 소해면상뇌증의 예방 또는 치료용 조성물
KR102041485B1 (ko) * 2017-09-25 2019-11-06 제주대학교 산학협력단 3,4-디-카페오일퀴닌산을 포함하는, 활성산소종, 자외선 또는 미세먼지에 대한 피부 보호용 화장료 조성물
JP7346394B2 (ja) 2017-10-06 2023-09-19 カーギル インコーポレイテッド 感覚変更化合物
FR3080033B1 (fr) * 2018-04-12 2020-07-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouvelle composition a base d'acides polycafeoylquiniques, son utilisation en cosmetique et compositions cosmetiques en comprenant
AU2019272960A1 (en) * 2018-05-24 2020-12-10 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
KR20200050068A (ko) * 2018-10-31 2020-05-11 고려대학교 산학협력단 3,5-디카페올리퀴닉산을 유효성분으로 함유하는 피부장벽 손상 개선용 및/또는 피부 염증 완화용 조성물
CN109674777A (zh) * 2019-01-16 2019-04-26 中国科学院成都生物研究所 异绿原酸类化合物在制备神经退行性疾病和忧郁症的药物中的应用
CA3135185A1 (en) 2019-04-06 2020-10-15 Cargill, Incorporated Sensory modifiers
CA3135584A1 (en) 2019-04-06 2020-10-15 Cargill, Incorporated Methods for making botanical extract composition
CN112076186B (zh) * 2020-08-24 2024-01-30 福建众安药业有限公司 一种3,4,5-o-三咖啡酰基奎宁酸在放射治疗中作为细胞保护剂的应用
KR102338415B1 (ko) * 2021-04-28 2021-12-09 조선대학교 산학협력단 3,4-디카페오일퀴닉산을 포함하는 골관절염 예방 또는 치료용 약학 조성물
KR102338416B1 (ko) * 2021-04-28 2021-12-09 조선대학교 산학협력단 4,5-디카페오일퀴닉산을 포함하는 골관절염 예방 또는 치료용 약학 조성물
CN113973806B (zh) * 2021-11-06 2022-08-02 昆明时光肌生物技术有限公司 一种维持脐带间充质干细胞活性的保存液及保存方法
KR20230130479A (ko) * 2022-03-03 2023-09-12 서울대학교병원 안구건조증 또는 마이봄샘 기능장애의 예방, 개선, 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693105B1 (fr) * 1992-07-01 1994-09-02 Oreal Composition cosmétique et/ou dermatologique à action dépigmentante contenant un acide di- ou tri-caféoylquinique ou un mélange de ceux-ci.
EP1283037A4 (en) * 2000-04-11 2006-02-22 Takara Bio Inc REMEDIES
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
CN1173707C (zh) * 2001-04-23 2004-11-03 深圳市生物谷科技有限公司 一种含野黄芩甙和咖啡酰奎宁酸的药用组合物
JP4644500B2 (ja) * 2005-02-03 2011-03-02 アピ株式会社 細胞分化誘導剤及びその製造方法
ES2891179T3 (es) * 2005-05-20 2022-01-26 Jack L Arbiser Inhibidores de proteasoma y sus usos
CN100382798C (zh) * 2006-01-20 2008-04-23 深圳市生物谷科技有限公司 一种含有咖啡酰奎宁酸的药物组合物
DE102006031762A1 (de) * 2006-07-05 2008-01-10 Lancaster Group Gmbh Kosmetische Zubereitung mit einem Hautpflegekomplex mit Anti-Alterungswirkung
CN101057678B (zh) * 2007-06-13 2010-09-01 深圳市金沙江投资有限公司 一种含有天然植物提取物或单体的组合物
JP5403582B2 (ja) * 2008-11-21 2014-01-29 国立大学法人 筑波大学 Ａｔｐ産生促進剤
EP2324840B1 (en) * 2009-11-18 2019-03-20 Croda Italiana S.p.A. Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia
CN102266318A (zh) * 2011-05-23 2011-12-07 中国人民解放军第二军医大学 咖啡酰奎宁酸及其衍生物在制备抗补体药物中的应用
WO2013192073A2 (en) * 2012-06-18 2013-12-27 The Procter & Gamble Company Method of improving the appearance of aging skin

Also Published As

Publication number Publication date
BR112016006926B1 (pt) 2020-09-24
BR112016006926A2 (pt) 2017-08-01
US20160228394A1 (en) 2016-08-11
EP3052074A1 (en) 2016-08-10
GB201317286D0 (en) 2013-11-13
WO2015044649A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
BR112016006926A8 (pt) uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112014029442A2 (pt) composições antimucosas à base de xilitol e métodos e composições relacionados
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112014016808A8 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112013000537A2 (pt) composição aquosa contendo bromexina
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
BR112014016648A8 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
BR112012028451A2 (pt) composição tópica de iodopovidona
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112016002643A8 (pt) composições para tratamento de pele e método para produção de uma composição para tratamento de pele
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2014, OBSERVADAS AS CONDICOES LEGAIS.